Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.

ABSTRACT:

Background

Breast cancer is the second leading cause of cancer-related death in women, and drug resistance during treatment is a major challenge. However, the mechanisms underlying drug resistance are not fully understood. Here we applied whole-exome sequencing (WES) to clarify resistant rules to Herceptin and tyrosine kinase inhibitors (TKIs).

Methods

There are 12 HER2+ breast cancer patients who were done WES. Samples from tumor and surrounding tissues underwent DNA sequencing and analysis. Various experimental and bioinformatics techniques were employed, including genomic capture, mutation analysis (Genome Analysis Toolkit (GATK), etc.), bioinformatics assessments, and drug-gene interaction investigations. Ultimately, the study explored the association of APOB gene expres

SUBMITTER: Guo L 

PROVIDER: S-EPMC10799408 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature